Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR1800 Safety and PK in Stable COPD
NCT04759807Phase 1Completed
- Sponsor
- Pulmatrix, Inc.
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PUR1800 in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Pulmatrix, Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of intraday FEV1 declines of >=10%, >=15%, and >=20% and 7 more. Started Jan 2021; status: completed.
02
Drugs
PUR1800
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04759807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04759807.